Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Puma Biotechnology revenue
Puma Biotechnology's revenue is $230.5 million.
What is Puma Biotechnology's revenue?
- Puma Biotechnology's revenue growth from 2017 to 2024 is 732.47%.
- Puma Biotechnology has 265 employees, and the revenue per employee ratio is $869,690.
- Puma Biotechnology's peak quarterly revenue was $99.1M in 2019(q1).
- Puma Biotechnology peak revenue was $272.3M in 2019.
- Puma Biotechnology annual revenue for 2023 was 235.6M, 3.34% growth from 2022.
- Puma Biotechnology annual revenue for 2024 was 230.5M, -2.19% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Puma Biotechnology historical revenue
Puma Biotechnology's peak revenue was $272.3M in 2019. The peak quarterly revenue was $99.1M in 2019(q1).
Puma Biotechnology's revenue increased from $27.7m in 2017 to $230.5M currently. That's a 732.47% change in annual revenue.
Puma Biotechnology annual revenue
Puma Biotechnology annual revenue over time
| Fiscal year / year | Puma Biotechnology revenue |
|---|---|
| 2017 | $27.7M |
| 2018 | $251.0M |
| 2019 | $272.3M |
| 2020 | $225.1M |
| 2021 | $253.2M |
| 2022 | $228.0M |
| 2023 | $235.6M |
| 2024 | $230.5M |
Rate Puma Biotechnology's financial transparency
Puma Biotechnology annual growth
Puma Biotechnology saw the greatest revenue growth in 2018, when revenue increased by 806.6%.
Puma Biotechnology had the lowest revenue growth in 2020, when revenue changed by -17.32%.
Puma Biotechnology annual growth rate over time
| Year | Puma Biotechnology growth |
|---|---|
| 2018 | 807%↑ |
| 2019 | 8%↑ |
| 2020 | -17%↓ |
| 2021 | 12%↑ |
| 2022 | -10%↓ |
| 2023 | 3%↑ |
| 2024 | -2%↓ |
Puma Biotechnology quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Puma Biotechnology quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2017 | - | - | $6.1M | $21.6M |
| 2018 | $66.5M | $50.8M | $62.6M | $71.1M |
| 2019 | $99.1M | $53.9M | $56.4M | $62.9M |
| 2020 | $51.2M | $70.6M | $50.8M | $52.6M |
| 2021 | $98.2M | $53.4M | $46.2M | $55.4M |
| 2022 | $45.7M | $59.5M | $57.1M | $65.7M |
| 2023 | $52.8M | $54.6M | $56.1M | $72.2M |
| 2024 | $43.8M | $47.1M | $80.5M | $59.1M |
Puma Biotechnology jobs nearby
Do you work at Puma Biotechnology?
Is Puma Biotechnology transparent about its revenue structure?
Puma Biotechnology financial information
| CEO | Alan H. Auerbach |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 265 |
| Date Founded | 2010 |
| Headquarters | Los Angeles, California |
| Number of Locations | 2 |
| Revenue | $230.5M |
| Net Income | $2,000 |
| Gross Proft | $166.1M (2024) |
| PE Ratio | 35.11 |
| Tax Rate | -0.3% |
| Market Capitalization | $1.1B |
| Total Assets | $222,059,000 |
| Ticker | PBYI |
Puma Biotechnology jobs you might like
Puma Biotechnology financing
Puma Biotechnology received early financing of $55.0M on 2011-10-05.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $55M | 10/2011 |
| Post Ipo Equity | $129.3M | 02/2014 |
| Post Ipo Equity | $218M | 01/2015 |
| Post Ipo Equity | $172M | 10/2016 |
| Post Ipo Equity | $100M | 11/2017 |
| Post Ipo Debt | $125M | 07/2021 |
| Post Ipo Equity | $10M | 03/2022 |
Puma Biotechnology investors
| Investors | Security type |
|---|---|
| Jennison Associates | Post Ipo Equity |
| Tekla Capital Management | Post Ipo Equity |
| SAHSEN VENTURES LLC | Post Ipo Equity |
| H&Q Healthcare Investors | Post Ipo Equity |
| Adage Capital Management | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
| T. Rowe Price Group, Inc. | Post Ipo Equity |
| Bain Capital Public Equity | Post Ipo Equity |
| Oxford Finance LLC | Post Ipo Equity |
| Silicon Valley Bank | Post Ipo Equity |
| Athyrium Capital Management LP | Post Ipo Debt |
| Armentum Partners | Post Ipo Debt |
| Athyrium Capital Management LP | Post Ipo Equity |
| Alan H Auerbach | Post Ipo Equity |
Puma Biotechnology competitors
Puma Biotechnology's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Puma Biotechnology's smallest competitor is Human Genome Sciences with revenue of $131.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Neurocrine Biosciences | $78,232 | $2.4B | 400 | 373 |
| Regeneron | $85,589 | $14.2B | 9,123 | 317 |
| Merck | $90,328 | $64.2B | 74,000 | 2,290 |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 692 |
| Cubist Pharmaceuticals | $91,725 | $926.4M | 873 | - |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,498 |
| Amneal Pharmaceuticals | $76,227 | $2.8B | 6,500 | 89 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Puma Biotechnology, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Puma Biotechnology. The employee data is based on information from people who have self-reported their past or current employments at Puma Biotechnology. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Puma Biotechnology. The data presented on this page does not represent the view of Puma Biotechnology and its employees or that of Zippia.
Puma Biotechnology may also be known as or be related to PUMA BIOTECHNOLOGY INC., PUMA BIOTECHNOLOGY, INC., Puma Biotechnology, Puma Biotechnology Inc, Puma Biotechnology Ltd, Puma Biotechnology, Inc and Puma Biotechnology, Inc.